1 / 1

Deeley Research Centre, BC Cancer Agency

Deeley Research Centre, BC Cancer Agency.

aretha-knox
Download Presentation

Deeley Research Centre, BC Cancer Agency

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Deeley Research Centre, BC Cancer Agency Dr. Nelson received training at the University of California at Berkeley (Ph.D.) and Fred Hutchinson Cancer Research Center (postdoc), and in 2003 became founding Director of the Deeley Research Centre. His laboratory is interested in the development of immune-based therapies for cancer. Areas of focus include: defining the effects of standard treatments on the immune response to cancer; understanding how cytokine signals modulate the anti-tumour activity of tumour-infiltrating T cells; and using genomic approaches to identify novel tumour mutations that can serve as target antigens for immunotherapy. Brad H. Nelson, Ph.D. Director & Senior Scientist, DRC Associate Professor, UBC Adjunct Associate Professor, UVIC Dr. Watson began his medical training at the University of Cambridge and St. Thomas’ Hospital and completed speciality training in Pathology at the University of Manitoba, where he served on faculty from 1993. He joined the BC Cancer Agency in 2005 to become the Director of the Tumour Tissue Repository and more recently Chief Physician of the Vancouver Island Cancer Centre in 2009. Dr. Watson has a long-standing interest in the molecular pathology and biomarkers of breast cancer. His laboratory has pioneered work on S100A7 and its role in breast cancer progression. Peter H. Watson, M.D. Director, Tumour Tissue Repository Physician-in-Chief, VIC Adjunct Professor, UBC and UVIC Dr. Lum obtained his Ph.D. from the University of Ottawa and pursued a post-doctoral fellowship at the University of Pennsylvania with Craig Thompson. His research program is interested in understanding how cellular metabolism regulates tumorigenesis. He is studying how autophagy promotes tumour cell survival and studying whether these pathways can be used as novel targets for T cell therapy. Julian J. Lum, Ph.D. Research Scientist, DRC Adjunct Assistant Professor - UVIC Dr. Webb completed his graduate training at the University of British Columbia and spent several years working in industry before becoming a faculty member at the University of Ottawa. Following this, he returned to industry and developed an interest in vaccines for human malignancies. Dr. Webb joined the Deeley Research Centre as the T cell Projects Leader continuing his work in cancer immunotherapy. In addition, Dr. Webb has been studying new vaccine strategies to induce T cell-mediated immune responses. John Webb, Ph.D. Leader, T Cell Projects Adjunct Associate Professor - UVIC UBC: University of British Columbia UVIC: University of Victoria DRC: Deeley Research Centre VIC: Vancouver Island Centre LEGEND

More Related